比罗尼布 | 251111-30-5

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 中文名称: 比罗尼布
• 中文别名: 贝洛拉尼卜
• 英文名称: CKD-732
• 英文别名: Beloranib；[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] (E)-3-[4-[2-(dimethylamino)ethoxy]phenyl]prop-2-enoate
• CAS: 251111-30-5
• 化学式: C₂₉H₄₁NO₆
• 分子量: 499.648
• InChiKey: ZEZFKUBILQRZCK-MJSCXXSSSA-N

物化性质

• 沸点：
  604.1±55.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、乙酸乙酯（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  36
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  73.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  比罗尼布 在 双氧水 作用下， 以 丙酮 为溶剂， 反应 8.0h， 以80%的产率得到3-[4-(2-dimethylaminoethoxy)phenyl]acrylic acid 5-methoxy-4-[2-methyl-3-(3-methylbut-2-enyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl ester N-oxide
  参考文献：
  名称：

  Selective N-Demethylation of Tertiary Aminofumagillols with Selenium Dioxide via a Non-classical Polonovski Type Reaction

  摘要：

  DOI：

  10.3987/com-06-10683
• 作为产物：
  描述：

  (E)-3-[4-[2-(dimethylamino)ethoxy]phenyl]prop-2-enoyl chloride 、 5-甲氧基-4-[2-甲基-3-(3-甲基丁-2-烯基)环氧乙烷-2-基]-1-氧杂螺[2.5]辛烷-6-醇 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以256 mg的产率得到比罗尼布
  参考文献：
  名称：

  Effective Procedure for the Oxidative Cleavage of Olefins by OsO4-NaIO4

  摘要：

  Oxidative cleavage of olefins by OsO4-NaIO4 sometimes suffers from low yields due to the formation of side products. It is reported that the addition of pyrimidine can suppress the side reactions and dramatically improve the yield of this classic reaction.

  DOI：

  10.3987/com-09-11689

文献信息

• Fumigillol compounds and methods of making and using same
  申请人：Zafgen, Inc.

  公开号：US10220015B2

  公开（公告）日：2019-03-05

  The disclosure provides fumagillol type compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided.

  本公开提供了烟曲霉素类化合物及其在治疗肥胖症等疾病中的用途。提供了药物组合物和使用方法，例如治疗肥胖症的方法。
• FUMIGILLOL TYPE COMPOUNDS AND METHODS OF MAKING AND USING SAME
  申请人：Zafgen, Inc.

  公开号：EP2850079B1

  公开（公告）日：2018-05-02
• Methods and Compositions for Treating Cardiovascular Disorders
  申请人：Hughes Thomas E.

  公开号：US20130023513A1

  公开（公告）日：2013-01-24

  The invention generally relates to methods of treating a patient having, and/or at risk of, cardiovascular or cerebrovascular disorders. Such methods may include administering a MetAP2 inhibitor at a dose that does not substantially modulate angiogenesis.
• Methods of Treating a Subject with Benign Prostate Hyperplasia
  申请人：Vath James E.

  公开号：US20130052283A1

  公开（公告）日：2013-02-28

  The invention generally relates to methods of treating a male subject with a prostate condition, for example, benign prostate hyperplasia (BPH). In certain embodiments, the invention provides methods of treating a male subject with a prostate condition, which include administering a MetAP2 inhibitor at a dose that does not substantially modulate angiogenesis.
• METHODS OF TREATING AGE RELATED DISORDERS
  申请人：Zafgen, Inc.

  公开号：US20140336251A1

  公开（公告）日：2014-11-13

  The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enhancing the cognitive function of a patient in need thereof. Such methods may include administering a therapeutically effective amount of a MetAP2 inhibitor.